Compare Stocks → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:BLCMNASDAQ:CINGNASDAQ:CNTXNASDAQ:NERV Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLCMBellicum Pharmaceuticals$0.07-6.6%$0.08$0.06▼$1.31$727K1.3922,874 shs6,000 shsCINGCingulate$0.88-0.1%$1.10$0.75▼$23.80$4.40M-0.95323,711 shs175,709 shsCNTXContext Therapeutics$1.32-6.4%$1.22$0.47▼$1.69N/A2.1753,032 shs5,702 shsNERVMinerva Neurosciences$2.48-0.8%$4.07$2.26▼$13.49$17.34M0.21106,129 shs11,384 shs20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLCMBellicum Pharmaceuticals0.00%0.00%0.00%-29.13%-82.11%CINGCingulate+0.69%-8.04%-18.52%-80.53%-95.77%CNTXContext Therapeutics-1.44%-9.87%+24.55%+23.42%+101.50%NERVMinerva Neurosciences+1.62%-1.18%-5.28%-66.67%-17.97%Biden’s $374B Giveaway Into This Sector (Ad)Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right hereClick here for the full storyMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBLCMBellicum PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACINGCingulate2.2743 of 5 stars3.24.00.00.01.24.20.0CNTXContext Therapeutics1.7211 of 5 stars3.55.00.00.00.60.00.6NERVMinerva Neurosciences3.1084 of 5 stars3.03.00.04.62.00.00.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLCMBellicum PharmaceuticalsN/AN/AN/AN/ACINGCingulate2.33Hold$8.00810.02% UpsideCNTXContext Therapeutics3.00Buy$4.00203.03% UpsideNERVMinerva Neurosciences2.00Hold$11.00343.55% UpsideCurrent Analyst RatingsLatest NERV, CNTX, BLCM, and CING Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/21/2024CNTXContext TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$5.00 ➝ $4.002/27/2024NERVMinerva NeurosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$11.00(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLCMBellicum Pharmaceuticals$1.50M0.48N/AN/A$0.23 per share0.33CINGCingulateN/AN/AN/AN/A($5.88) per shareN/ACNTXContext TherapeuticsN/AN/AN/AN/A$0.74 per shareN/ANERVMinerva NeurosciencesN/AN/AN/AN/A($4.07) per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLCMBellicum Pharmaceuticals-$24.97MN/A0.00∞N/AN/AN/A-157.93%N/ACINGCingulate-$23.53M-$32.60N/A∞N/AN/AN/A-432.81%5/8/2024 (Estimated)CNTXContext Therapeutics-$23.96M-$1.50N/AN/AN/AN/A-115.50%-97.04%5/8/2024 (Estimated)NERVMinerva Neurosciences-$30M-$4.65N/AN/AN/AN/AN/A-50.27%5/20/2024 (Estimated)Latest NERV, CNTX, BLCM, and CING EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/21/2024Q4 2023CNTXContext Therapeutics-$0.35-$0.42-$0.07-$0.42N/AN/A2/22/2024Q4 2023NERVMinerva Neurosciences-$0.88-$1.19-$0.31-$1.19N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBLCMBellicum PharmaceuticalsN/AN/AN/AN/AN/ACINGCingulateN/AN/AN/AN/AN/ACNTXContext TherapeuticsN/AN/AN/AN/AN/ANERVMinerva NeurosciencesN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLCMBellicum PharmaceuticalsN/A3.043.04CINGCingulateN/A0.060.06CNTXContext TherapeuticsN/A3.833.83NERVMinerva NeurosciencesN/A12.5712.58OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLCMBellicum Pharmaceuticals4.93%CINGCingulate41.31%CNTXContext Therapeutics14.03%NERVMinerva Neurosciences34.56%Insider OwnershipCompanyInsider OwnershipBLCMBellicum Pharmaceuticals10.30%CINGCingulate38.43%CNTXContext Therapeutics6.66%NERVMinerva Neurosciences6.40%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBLCMBellicum Pharmaceuticals139.72 million8.72 millionNot OptionableCINGCingulate155.01 million3.09 millionNot OptionableCNTXContext Therapeutics5N/AN/ANot OptionableNERVMinerva Neurosciences96.99 million6.55 millionNot OptionableNERV, CNTX, BLCM, and CING HeadlinesSourceHeadlineMinerva Neurosciences (NASDAQ:NERV) Shares Pass Below 200 Day Moving Average of $5.76americanbankingnews.com - April 12 at 3:24 AMCrestwood softball doomed by defensive miscues in loss to Minervaweeklyvillager.com - April 4 at 8:40 PMPrairie voles display signs of human-like depression, show promise as animal modelmsn.com - April 4 at 8:40 PMAndreas Martinos firm Minerva Marine sells aframax tanker after newbuilding orderstradewindsnews.com - April 4 at 7:34 AMHere Comes Rutgers Dayrutgers.edu - April 1 at 10:14 AMNew track and field season gives Minerva sprinter Kyleigh Lippincott a fresh startmsn.com - March 31 at 2:50 AMIrish singer/songwriter Enda Reilly to perform in Minerva on April 12reviewonline.com - March 28 at 9:43 PMReuben Norman litter picking at Minerva Primary Schoolsomersetcountygazette.co.uk - March 28 at 9:43 PMF|T: The FinTech Times – Minerva chases anti-money laundering big leaguesbetakit.com - March 18 at 7:55 PMBMS completes $14bn takeover of Karunapharmaphorum.com - March 18 at 7:55 PMMinerva Porras, 86riverheadlocal.com - March 17 at 12:39 PMSocial factors taskforce launches guidance with support from Minervamanifest.co.uk - March 15 at 1:01 PMPotts Point homelessness encampment moved on from Minerva-Metro Theatre sitemsn.com - March 14 at 9:56 PMMinerva Named "One to Watch" in Chartis Financial Crime and Compliance 50 Rankingstmcnet.com - March 14 at 9:56 PMRenovated Manti Temple, preserved Minerva Teichert murals ready for 3-week public open housemsn.com - March 13 at 10:46 PMPotts Point homelessness encampment moved on by Minerva-Metro Theatre developer ownersnews.com.au - March 13 at 10:46 PMMinerva Named Top AI & Data Product in the 2024 Product Awardstmcnet.com - March 13 at 12:45 PMAcadia pulls trials of pimavanserin after schizophrenia failpharmaphorum.com - March 12 at 8:51 AMFDA Delays Approval of Roluperidone for Schizophrenia Treatmentmedindia.net - February 29 at 3:38 PMFDA Denies Approval of Roluperidone for Negative Symptoms of Schizophreniaempr.com - February 28 at 6:41 PMMinerva slumps as FDA finds fault with schizophrenia filingpharmaphorum.com - February 28 at 8:40 AMMinerva hit with FDA rejection for schizophrenia symptom drugpharmaceutical-technology.com - February 28 at 8:40 AMHold Rating on Minerva Neurosciences Amid FDA Setbacks and Financial Constraintsmarkets.businessinsider.com - February 27 at 7:53 PMMinerva schizophrenia drug rejected by FDAfinance.yahoo.com - February 27 at 2:50 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsBellicum PharmaceuticalsNASDAQ:BLCMBellicum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also include BPX-603, an autologous dual-switch GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing human epidermal growth factor receptor 2 antigen. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is based in Houston, Texas.CingulateNASDAQ:CINGCingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders intended for children, adolescents, and adults. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.Context TherapeuticsNASDAQ:CNTXContext Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors in the United States. It develops CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.Minerva NeurosciencesNASDAQ:NERVMinerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.